Exozymes Inc.
EXOZFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Exozymes Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Source: Exozymes Inc. — 10-K filed Mar 31, 2025
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 3 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Apr 10, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| BlackRock, Inc. | 2026-03-31 | 6,797 | $51K | SEC filing |
| UBS Group AG | 2026-03-31 | 24 | $180 | SEC filing |
| Tower Research Capital LLC (TRC) | 2026-03-31 | 1,317 | $9.89K | SEC filing |
| GEODE CAPITAL MANAGEMENT, LLC | 2026-03-31 | 21,891 | $164K | SEC filing |
| MORGAN STANLEY | 2026-03-31 | 1,250 | $9.39K | SEC filing |
| Tower Research Capital LLC (TRC) | 2025-12-31 | 2 | Not shown | SEC filing |
| GEODE CAPITAL MANAGEMENT, LLC | 2025-12-31 | 23,562 | Not shown | SEC filing |
| MORGAN STANLEY | 2025-12-31 | 1,250 | Not shown | SEC filing |
| VANGUARD GROUP INC | 2025-12-31 | 31,516 | Not shown | SEC filing |
| MORGAN STANLEY | 2025-12-31 | 1,250 | Not shown | SEC filing |
| BANK OF AMERICA CORP /DE/ | 2025-12-31 | 17 | Not shown | SEC filing |
| BlackRock, Inc. | 2025-12-31 | 6,251 | Not shown | SEC filing |
| UBS Group AG | 2025-12-31 | 3 | Not shown | SEC filing |
| VANGUARD GROUP INC | 2025-09-30 | 25,981 | $383K | SEC filing |
| BANK OF AMERICA CORP /DE/ | 2025-09-30 | 23 | $332 | SEC filing |
| MORGAN STANLEY | 2025-09-30 | 1,250 | $18K | SEC filing |
| BANK OF AMERICA CORP /DE/ | 2025-09-30 | 23 | $332 | SEC filing |
| GEODE CAPITAL MANAGEMENT, LLC | 2025-09-30 | 23,063 | $340K | SEC filing |
| MORGAN STANLEY | 2025-09-30 | 1,250 | $18K | SEC filing |
| BlackRock, Inc. | 2025-09-30 | 4,985 | $71.9K | SEC filing |
- Each value is checked against Exozymes Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 8 rows: no share price from within three months of their report dates is on file, so they could not be checked.
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.
- GEODE CAPITAL MANAGEMENT, LLC: 23,562 shares reported 2025-12-31; 21,891 shares reported 2026-03-31.
- Tower Research Capital LLC (TRC): 2 shares reported 2025-12-31; 1,317 shares reported 2026-03-31.
- UBS Group AG: 3 shares reported 2025-12-31; 24 shares reported 2026-03-31.
- BlackRock, Inc.: 6,251 shares reported 2025-12-31; 6,797 shares reported 2026-03-31.
- GEODE CAPITAL MANAGEMENT, LLC: 23,063 shares reported 2025-09-30; 23,562 shares reported 2025-12-31.
- Tower Research Capital LLC (TRC): 344 shares reported 2025-06-30; 2 shares reported 2025-12-31.
- UBS Group AG: 4,621 shares reported 2025-09-30; 3 shares reported 2025-12-31.
- BlackRock, Inc.: 4,985 shares reported 2025-09-30; 6,251 shares reported 2025-12-31.
- VANGUARD GROUP INC: 25,981 shares reported 2025-09-30; 31,516 shares reported 2025-12-31.
- GEODE CAPITAL MANAGEMENT, LLC: 20,599 shares reported 2025-06-30; 23,063 shares reported 2025-09-30.
- UBS Group AG: 5,014 shares reported 2025-06-30; 4,621 shares reported 2025-09-30.
- BlackRock, Inc.: 4,841 shares reported 2025-06-30; 4,985 shares reported 2025-09-30.
Showing the 12 most recent filer reports.
2 filers have only one report here.
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-04-09 | Korman Tyler Paz · Chief Scientific Officer | COMMON STOCK | S — Open market or private sale | −750 | 10.53 | SEC filing |
| 2026-04-08 | Korman Tyler Paz · Chief Scientific Officer | COMMON STOCK | S — Open market or private sale | −750 | 10.04 | SEC filing |
| 2025-07-02 | Heltzen Michael · Chief Executive Officer | Common Stock | P — Open market or private purchase | +1,040 | 10.22 | SEC filing |
| 2025-01-17 | Heltzen Michael · Chief Executive Officer | Common Stock | P — Open market or private purchase | +1,767 | 10.78 | SEC filing |
| 2025-01-16 | Heltzen Michael · Chief Executive Officer | Common Stock | P — Open market or private purchase | +121 | 10.72 | SEC filing |
| 2024-11-15 | Heltzen Michael · Chief Executive Officer | Common Stock | P — Open market or private purchase | +1,984 | 11.10 | SEC filing |
Showing 6 of 6 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-04-01 | Nawaz Fouad · Vice President- Finance | COMMON STOCK | A — Grant, award, or other acquisition | +5,999 | SEC filing |
| 2026-04-01 | Perriman Damien Alan · Chief Commercial Officer | Restricted Stock Grant for Common Stock | A — Grant, award, or other acquisition | +62,759 | SEC filing |
| 2026-04-01 | Opgenorth Paul Hideo · Vice President, Development | COMMON STOCK | A — Grant, award, or other acquisition | +3,999 | SEC filing |
| 2026-04-01 | Perriman Damien Alan · Chief Commercial Officer | Stock Option for Common Stock | A — Grant, award, or other acquisition | +146,437 | SEC filing |
| 2026-04-01 | Perriman Damien Alan · Chief Commercial Officer | COMMON STOCK | A — Grant, award, or other acquisition | +8,887 | SEC filing |
| 2026-04-01 | Korman Tyler Paz · Chief Scientific Officer | COMMON STOCK | A — Grant, award, or other acquisition | +5,332 | SEC filing |
| 2025-06-17 | Heltzen Michael · Chief Executive Officer | Stock Options for Common Stock | A — Grant, award, or other acquisition | +235,817 | SEC filing |
| 2025-06-16 | Korman Tyler Paz · Vice President, Research | Common Stock | A — Grant, award, or other acquisition | +2,990 | SEC filing |
Showing 8 of 12 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.